Manipal Health Enterprises to acquire Kinder Women's Hospital in Bengaluru

Manipal Health Enterprises will acquire Kinder Women's Hospital in Bengaluru for Rs 130 crore. This business transfer agreement involves acquiring the hospital's entire operations and assets. The acquisition strengthens Manipal Hospitals' position in a growing Bengaluru healthcare market. It will also expand access to their clinical expertise and capabilities for more patients. This move complements their existing healthcare ecosystem in the Whitefield micro-market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YGcSIrw
via IFTTT

Read More

Healthcare delivery capital-intensive, hospital tariffs only tip of iceberg: NATHEALTH

Healthcare delivery costs are capital-intensive and investment-heavy, according to NATHEALTH. Policy discussions should address structural costs like land and manpower. Hospitals require continuous investment in infrastructure and specialized equipment. The industry warns against regulatory changes that deter expansion and innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2IDifRN
via IFTTT

Read More

India's pharma sector must shift from cost competitiveness to innovation, global quality: Experts

For the growth of India's pharmaceutical sector, prioritizing innovation and advanced manufacturing is essential. Experts indicate that increasing investments in research and digital technologies could propel the market to an impressive USD 130 billion by 2030. Companies must also elevate their quality and comply with global regulatory expectations to compete in the global landscape, thus establishing India as an innovation hub in life sciences.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ILvMO8R
via IFTTT

Read More

Lupin gets USFDA nod for generic tablets to treat excessive daytime sleepiness

Pharma major Lupin Ltd announced receiving final USFDA approval for its generic Pitolisant tablets. These tablets are indicated for treating excessive daytime sleepiness in patients. The US health regulator approved strengths of 4.45 mg and 17.8 mg. Lupin's Pitolisant tablets are bioequivalent to Wakix, a prescription medicine. This approval marks a significant step for the company in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EmgD0VJ
via IFTTT

Read More

Aurobindo Pharma’s Raleigh plant gets 'Voluntary Action Indicated' classification from US FDA

Aurobindo Pharma's US facility received a Voluntary Action Indicated classification. The US FDA closed its inspection of the Raleigh manufacturing plant. This classification allows applications for inhalers and other products to proceed. The inspection covered inhaler, dermatology, and transdermal product manufacturing operations. The company's regulatory filing confirmed the inspection closure and VAI status.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0Vnv42K
via IFTTT

Read More

India plans national sports medicine framework ahead of 2036 Olympics

India plans a national sports medicine framework for preventive athlete care. This initiative aims to standardize injury protocols and link medical institutions. The government considers a phased rollout by 2028 for this new system. This framework will improve athlete availability and long-term career sustainability. The proposal supports India's potential 2036 Olympic Games bid.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7stunQp
via IFTTT

Read More

In private healthcare's rise, price points are a big pain

In a recent proposal, a parliamentary committee has recommended that hospital room charges not exceed the rates of three-star hotels. The substantial growth of private healthcare as an industry has attracted considerable private equity investment, resulting in valuation spikes and shifts in ownership among hospital chains. However, this raises important questions about the accessibility of healthcare for the average person.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UQe6Rc9
via IFTTT

Read More